← Eichor
Study identifier: NCT06252142 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study for Wait and Watch Suitable in Rectal Cancer

Condition: Rectal Neoplasms  ·  Sponsor: Tata Memorial Centre

PhaseN/A
Planned participants260
Who can joinAll sexes, 18 Years to 90 Years
Healthy volunteersNo

About this study

One of the standard treatment options offered to patients of locally advanced rectal cancer is neoadjuvant (treatment given before surgery) radiotherapy \& chemotherapy followed by surgery. In patients whose tumour has completely reduced after neoadjuvant treatment, the wait and watch strategy is also an option. This is another standard treatment option for patients of locally advanced rectal cancers. In this, the patient is monitored after treatment completion. In this study, investigators are only going to observe the patient's response to treatment, monitor their side-effects due to treatment and assess their quality of life using standardized quality of life questionnaires. No additional tests or hospital visits will be required as a part of this study. The patient will be followed up, as per standard follow-up protocol, for at least 2 years after the completion of their treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Rahul Krishnatry, MD  ·  022-24177000  ·  krishnatry@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Tata Memorial centreMumbai, Maharashtra, IndiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06252142